Folic acid reduces doxorubicin‐induced cardiomyopathy by modulating endothelial nitric oxide synthase

@inproceedings{Octavia2017FolicAR,
  title={Folic acid reduces doxorubicin‐induced cardiomyopathy by modulating endothelial nitric oxide synthase},
  author={Yanti Octavia and Georgios Kararigas and Martine de Boer and Ihsan Chrifi and Rinrada Kietadisorn and Melissa Swinnen and Hans J Q Duimel and Fons K. Verheyen and Maarten M. Brandt and D. Fliegner and Caroline C. Cheng and Stefan P. Janssens and Dirk Jan Duncker and An L. Moens},
  booktitle={Journal of cellular and molecular medicine},
  year={2017}
}
The use of doxorubicin (DOXO) as a chemotherapeutic drug has been hampered by cardiotoxicity leading to cardiomyopathy and heart failure. Folic acid (FA) is a modulator of endothelial nitric oxide (NO) synthase (eNOS), which in turn is an important player in diseases associated with NO insufficiency or NOS dysregulation, such as pressure overload and myocardial infarction. However, the role of FA in DOXO-induced cardiomyopathy is poorly understood. The aim of this study was to test the… CONTINUE READING
BETA